Contact this trialFirst, we need to learn more about you.
Anti-tumor antibiotic
CPX-351 +1 More for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
New York, New York
This trial is testing a new combination therapy of CPX-351 and gemtuzumab ozogamicin (GO) to treat acute myeloid leukemia (AML) in patients who are ineligible for standard intensive induction chemotherapy. The goal is to establish the safety and feasibility of the combination and to assess its efficacy and impact on patients' quality of life.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.